Adamis Pharmaceuticals Corp - FORM 10-K - EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - March 15, 2018

Attached files

file	filename
EX-32.2 - CERTIFICATION BY CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corp	ex32-2.htm
EX-32.1 - CERTIFICATION BY CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corp	ex32-1.htm
EX-31.2 - CERTIFICATION BY CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corp	ex31-2.htm
EX-31.1 - CERTIFICATION BY CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corp	ex31-1.htm
EX-23.1 - AUDITOR'S CONSENT - Adamis Pharmaceuticals Corp	ex23-1.htm
EX-10.79 - MARCH 2018 AMENDED AND RESTATED LINE OF CREDIT PROMISSORY NOTE - Adamis Pharmaceuticals Corp	ex10-79.htm
EX-10.78 - MARCH 2018 AMENDMENT TO LOAN AND SECURITY AGREEMENT - Adamis Pharmaceuticals Corp	ex10-78.htm
10-K - ANNUAL REPORT - Adamis Pharmaceuticals Corp	admp_10k-123117.htm

ADAMIS PHARMACEUTICALS CORPORATION 10-K

Exhibit 21.1

SUBSIDIARIES OF ADAMIS PHARMACEUTCALS CORPORATION.

Name		State of Incorporation
U.S. Compounding, Inc.		Arkansas
Biosyn, Inc.*		Pennsylvania
Adamis Corporation*		Delaware

*The inclusion of the subsidiary is not an admission by the Company that the subsidiaries, either individually or taken together, are “significant” under applicable SEC rules.